Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly used in managing type 2 diabetes.
• Recent trials indicate these agents reduce cardiac morbidity and hospitalization in diabetic populations.
• SGLT2 inhibitors demonstrate a favorable impact on the cardiorenal axis and metabolic profile compared to other diabetes pharmacotherapies.

Purpose of the Study:

• To review hypothesized mechanisms of cardioprotection offered by SGLT2 inhibitors.
• To present findings from recent clinical trials investigating SGLT2 inhibitors and novel therapies.
• To elucidate the pathophysiological evidence contributing to improved cardiac mechanics.

Main Methods:

• Systematic review of existing literature on SGLT2 inhibitors and cardiovascular outcomes.
• Analysis of data from landmark trials such as CANVAS and EMPA-REG OUTCOME.
• Evaluation of proposed mechanisms for cardioprotective effects.

Main Results:

• SGLT2 inhibitors are associated with reduced cardiac events and hospitalizations in patients with type 2 diabetes.
• Evidence suggests improvements in insulin resistance, inflammation, body weight, and serum triglycerides.
• Potential adverse effects include impacts on bone metabolism and increased risk of genitourinary infections.

Conclusions:

• SGLT2 inhibitors exhibit significant cardioprotective effects in type 2 diabetes management.
• Further research is needed to fully understand the direct pathophysiological mechanisms of cardiac benefit.
• Despite some adverse effects, SGLT2 inhibitors represent a promising therapeutic advancement.